These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19515414)

  • 1. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE; Van Gaal LF
    Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 4. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
    [No Abstract]   [Full Text] [Related]  

  • 6. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing diabetes drugs--helping clinical decisions?
    Thethi T; Fonseca V
    Lancet; 2013 Jan; 381(9861):93-4. PubMed ID: 23141811
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
    Ross SA; Ballantine J
    Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do different GLP-1 mimetics differ in their actions?
    Choukem SP; Gautier JF
    Curr Diab Rep; 2006 Nov; 6(5):365-72. PubMed ID: 17076997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
    Hansen KB; Knop FK; Holst JJ; Vilsbøll T
    Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 analogues for type 2 diabetes.
    Wilding JP; Hardy K
    BMJ; 2011 Feb; 342():d410. PubMed ID: 21325387
    [No Abstract]   [Full Text] [Related]  

  • 16. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
    Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide for type 2 diabetes?
    Drug Ther Bull; 2010 May; 48(5):50-3. PubMed ID: 20447980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
    Meier JJ
    Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
    Wroge J; Williams NT
    Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.